111 related articles for article (PubMed ID: 27533595)
1. Superagonist, Full Agonist, Partial Agonist, and Antagonist Actions of Arylguanidines at 5-Hydroxytryptamine-3 (5-HT
Alix K; Khatri S; Mosier PD; Casterlow S; Yan D; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2016 Nov; 7(11):1565-1574. PubMed ID: 27533595
[TBL] [Abstract][Full Text] [Related]
2. "Methylene Bridge" to 5-HT
Abdelkhalek AS; Alley GS; Alwassil OI; Khatri S; Mosier PD; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2019 Mar; 10(3):1380-1389. PubMed ID: 30375852
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the 5-HT3A receptor-mediated current by alkyl 4-hydroxybenzoates isolated from the seeds of Nelumbo nucifera.
Youn UJ; Lee JH; Lee YJ; Nam JW; Bae H; Seo EK
Chem Biodivers; 2010 Sep; 7(9):2296-302. PubMed ID: 20860031
[TBL] [Abstract][Full Text] [Related]
4. A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Sep; 170(2):391-402. PubMed ID: 23822584
[TBL] [Abstract][Full Text] [Related]
5. SR 57227A is a partial agonist/partial antagonist of 5-HT
Nakamura Y; Kondo M; Koyama Y; Shimada S
Biochem Biophys Res Commun; 2019 Jan; 508(2):590-596. PubMed ID: 30509492
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in 5-HT3 receptor pharmacology.
Thompson AJ
Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
[TBL] [Abstract][Full Text] [Related]
7. Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: a QSAR study.
Glennon RA; Daoud MK; Dukat M; Teitler M; Herrick-Davis K; Purohit A; Syed H
Bioorg Med Chem; 2003 Oct; 11(20):4449-54. PubMed ID: 13129581
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.
Trattnig SM; Harpsøe K; Thygesen SB; Rahr LM; Ahring PK; Balle T; Jensen AA
J Biol Chem; 2012 Jul; 287(30):25241-54. PubMed ID: 22589534
[TBL] [Abstract][Full Text] [Related]
9. Discriminating between 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Jun; 169(4):736-47. PubMed ID: 23489111
[TBL] [Abstract][Full Text] [Related]
10. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
[TBL] [Abstract][Full Text] [Related]
11. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
Gasiorek A; Trattnig SM; Ahring PK; Kristiansen U; Frølund B; Frederiksen K; Jensen AA
Biochem Pharmacol; 2016 Jun; 110-111():92-108. PubMed ID: 27086281
[TBL] [Abstract][Full Text] [Related]
12. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
[TBL] [Abstract][Full Text] [Related]
13. Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Lummis SC; Thompson AJ
Neuropharmacology; 2013 Oct; 73():241-6. PubMed ID: 23747573
[TBL] [Abstract][Full Text] [Related]
14. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
[TBL] [Abstract][Full Text] [Related]
15. Activation of human 5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site.
Lansdell SJ; Sathyaprakash C; Doward A; Millar NS
Mol Pharmacol; 2015 Jan; 87(1):87-95. PubMed ID: 25338672
[TBL] [Abstract][Full Text] [Related]
16. Direct modification of the 5-HT
Nakamura Y; Ishida Y; Kondo M; Shimada S
Eur J Pharmacol; 2018 Feb; 821():21-28. PubMed ID: 29277715
[TBL] [Abstract][Full Text] [Related]
17. VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Verheij MH; de Esch IJ; Lummis SC
J Pharmacol Exp Ther; 2012 May; 341(2):350-9. PubMed ID: 22306960
[TBL] [Abstract][Full Text] [Related]
18. Menthol inhibits 5-HT3 receptor-mediated currents.
Ashoor A; Nordman JC; Veltri D; Yang KH; Shuba Y; Al Kury L; Sadek B; Howarth FC; Shehu A; Kabbani N; Oz M
J Pharmacol Exp Ther; 2013 Nov; 347(2):398-409. PubMed ID: 23965380
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron-5-HT
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
[TBL] [Abstract][Full Text] [Related]
20. Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.
Lochner M; Lummis SC
Biophys J; 2010 Apr; 98(8):1494-502. PubMed ID: 20409468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]